Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 10/20 | 0.60 |
| ▸ | ANPEP | P15144 | 3/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15099380 | 0.88 | AGTR2 (0.61) | AGTR2ANPEPMMP2 | |
| SCHEMBL15099339 | 0.88 | AGTR2 (0.61) | AGTR2ANPEPMMP2 | |
| SCHEMBL15099416 | 0.88 | AGTR2 (0.61) | AGTR2ANPEPMMP2 | |
| SCHEMBL16356789 | 0.86 | AGTR2 (0.61) | AGTR2 | |
| SCHEMBL16356790 | 0.86 | AGTR2 (0.61) | AGTR2 | |
| SCHEMBL15099433 | 0.85 | AGTR2 (0.60) | AGTR2 | |
| SCHEMBL15099413 | 0.84 | AGTR2 (0.59) | AGTR2MMP2 | |
| SCHEMBL15099487 | 0.82 | AGTR2 (0.58) | AGTR2 | |
| SCHEMBL16356802 | 0.81 | AGTR2 (0.57) | AGTR2 | |
| SCHEMBL15099507 | 0.81 | AGTR2 (0.57) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370388-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| WO-2013102242-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370388-B2 | Heterocyclic compounds and methods of their use | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885ANPEP 197/4885MMP2 387/4885 |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885ANPEP 208/4885MMP2 391/4885 |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885ANPEP 208/4885MMP2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.